Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YANELY MD PINEIRO PUEBLA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1750702189
CMS profile
1311571
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$140.17

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $140.17 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $93.75 1
PFIZER INC. $35.18 2
Genentech USA, Inc. $11.24 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YANELY MD PINEIRO PUEBLA

NPI 1750702189 · CMS profile ID 1311571

Allopathic & Osteopathic Physicians / Internal Medicine

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
YANELY MD PINEIRO PUEBLA, NPI 1750702189, CMS profile ID 1311571, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1750702189?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $140.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $11.2412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 708853567 CMS
PFIZER INC. $21.7606/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672222413 CMS
Janssen Pharmaceuticals, Inc $93.7504/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659198283 CMS
PFIZER INC. $13.4202/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671932439 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $140.17 4
PY2021 $93.97 2
PY2022 $220.06 6
PY2023 $390.09 9
PY2024 $285.52 13
PY2025 $127.77 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $2,476,931.44 112
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $3,839,557.03 72
PY2023 Principal investigator $3,154,711.62 75
PY2022 Principal investigator $2,403,759.48 31
PY2021 Principal investigator $506,403.80 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $22,862.79 12/31/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419048
Principal investigator 1 PFIZER INC. $95,916.57 12/31/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130951375
Recipient PFIZER INC. $3,200.00 12/30/2024 Covered Recipient Physician NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1130903847
Principal investigator 1 PFIZER INC. $34,445.25 12/24/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130970702
Principal investigator 1 PFIZER INC. $6,587.40 12/20/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130950770
Principal investigator 1 PFIZER INC. $70,247.86 12/18/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130951386
Principal investigator 1 PFIZER INC. $17.86 12/12/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130921038
Principal investigator 1 PFIZER INC. $49,955.40 12/11/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130951381
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $485.00 12/10/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1155489358
Principal investigator 1 PFIZER INC. $8.46 12/10/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130921306
Principal investigator 1 PFIZER INC. $9,339.64 12/10/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130971100
Principal investigator 1 PFIZER INC. $8,234.25 12/06/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130951210
Principal investigator 1 PFIZER INC. $289,277.10 12/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130950775
Principal investigator 1 PFIZER INC. $127,499.68 11/26/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130985262
Principal investigator 1 PFIZER INC. $2,133.00 11/25/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130917623
Principal investigator 1 PFIZER INC. $25.38 11/21/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130920930
Principal investigator 1 PFIZER INC. $25.38 11/18/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130921310
Principal investigator 1 PFIZER INC. $30.08 11/09/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130920922
Principal investigator 1 PFIZER INC. $36,428.48 11/08/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130985473
Principal investigator 1 PFIZER INC. $633.96 11/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130920926
Principal investigator 1 PFIZER INC. $30.08 11/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130921034
Principal investigator 1 PFIZER INC. $1,452.24 11/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130921302
Principal investigator 1 PFIZER INC. $2,133.00 11/04/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130915992
Principal investigator 1 SANOFI US SERVICES INC. $17,121.00 10/15/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1128729418
Principal investigator 1 PFIZER INC. $22,435.23 10/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130995883
Principal investigator 1 PFIZER INC. $5,976.30 10/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1130995889
Principal investigator 1 PFIZER INC. $113,603.12 09/25/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131025132
Principal investigator 1 PFIZER INC. $137,634.05 09/25/2024 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131026409
Principal investigator 1 PFIZER INC. $175,022.31 09/11/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025138
Principal investigator 1 PFIZER INC. $85,914.51 09/04/2024 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131026404
Principal investigator 1 PFIZER INC. $218,177.76 08/06/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131026668
Principal investigator 1 PFIZER INC. $39,715.38 08/06/2024 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131026675
Principal investigator 1 PFIZER INC. $97,905.51 08/02/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131026710
Principal investigator 1 PFIZER INC. $22,875.32 08/02/2024 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131026716
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $74,351.01 07/19/2024 Non-covered Recipient Entity
Elias Research Associates Llc
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123477148
Principal investigator 1 Galderma Laboratories, L.P. $1,054.30 07/18/2024 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE INC
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab No dispute reported 06/30/2026 1156048995
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $455,967.24 07/17/2024 Non-covered Recipient Entity
Elias Research Associates Llc
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123477130
Principal investigator 1 PFIZER INC. $106,350.57 07/10/2024 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131026615
Principal investigator 1 PFIZER INC. $74,089.07 07/02/2024 Non-covered Recipient Entity
Palm Springs Community Health Center Corp
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131026663
Principal investigator 1 Galderma Laboratories, L.P. $3,074.24 06/13/2024 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE INC
A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab No dispute reported 06/30/2026 1156048803
Principal investigator 1 PFIZER INC. $51,384.48 06/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131028007
Principal investigator 1 PFIZER INC. $322.66 05/29/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027659
Principal investigator 1 PFIZER INC. $492,765.41 05/29/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027833
Principal investigator 1 PFIZER INC. $672.30 05/23/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131025273
Principal investigator 1 PFIZER INC. $637.60 05/23/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1131025365
Principal investigator 1 PFIZER INC. $18,387.00 05/11/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027861
Principal investigator 1 Amgen Inc. $18,200.00 04/20/2024 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096309027
Principal investigator 1 PFIZER INC. $20,107.20 04/16/2024 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130991861
Principal investigator 1 PFIZER INC. $4,266.00 04/15/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTS No dispute reported 06/30/2026 1130916357
Principal investigator 1 PFIZER INC. $2,650.00 04/10/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027839
Principal investigator 1 PFIZER INC. $86,880.46 04/05/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027665
Principal investigator 1 PFIZER INC. $1,350.10 04/04/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025191
Principal investigator 1 PFIZER INC. $975.40 03/30/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131027183
Principal investigator 1 PFIZER INC. $45,933.99 03/28/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027366
Principal investigator 1 PFIZER INC. $75,839.74 03/27/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027147
Principal investigator 1 PFIZER INC. $158,166.28 03/08/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027212
Principal investigator 1 PFIZER INC. $97,461.37 02/27/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131026639
Principal investigator 1 Amgen Inc. $2,861.99 02/26/2024 Non-covered Recipient Entity
ANGELS CLINICAL RESEARCH INSTITUTE
ASTRO P3 AD Adolescent Mono No dispute reported 06/30/2026 1096309599
Principal investigator 1 PFIZER INC. $7,654.50 02/24/2024 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130991849
Principal investigator 1 PFIZER INC. $1,250.00 02/21/2024 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130991770
Principal investigator 1 PFIZER INC. $81,619.44 02/14/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131026602
Principal investigator 1 PFIZER INC. $97,195.44 02/14/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027177
Principal investigator 1 PFIZER INC. $141,321.11 02/13/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027171
Principal investigator 1 PFIZER INC. $15,125.00 02/08/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131026644
Principal investigator 1 PFIZER INC. $7.52 01/24/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025196
Principal investigator 1 PFIZER INC. $117.40 01/24/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025202
Principal investigator 1 PFIZER INC. $2,133.00 01/22/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130916011
Principal investigator 1 PFIZER INC. $2,000.00 01/17/2024 Non-covered Recipient Entity
Angels Clinical Research Institute
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1130991855
Principal investigator 1 PFIZER INC. $469.60 01/17/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025260
Principal investigator 1 PFIZER INC. $176.10 01/16/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025266
Principal investigator 1 PFIZER INC. $11.28 01/16/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025359
Principal investigator 1 PFIZER INC. $30.08 01/16/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131025465
Principal investigator 1 PFIZER INC. $2,548.80 01/09/2024 Non-covered Recipient Entity
Palm Springs Community Health Center
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131027046